|VEDALAB is a veritable pioneer in the fields of immunodiagnostic and rapid test development.|
Created in 1991, VEDALAB is strongly committed to its partners to whom it supplies innovative diagnostic tests and reagents of an internationally recognized standard and quality.
Today, VEDALAB stands out as one of the most reputable companies in the field. Constantly and successfully expanding its competences, VEDALAB continually accepts new challenges in the ever-expanding diagnostic market, not only in human healthcare, but also in veterinary, environmental and diagnostic fields.
|Ebola Rapid Test|
VedaLab is very proud to announce that, in collaboration with the CEA (Commissariat à l'Energie Atomique), its very reputable R&D team has successfully developed the first ever rapid test for diagnosis of the Ebola virus. The test is performed with a small amount of serum, plasma or whole blood sample and the results (positive or negative) can be read within 10 to 15 minutes. A clinical field trial will be carried out during the coming weeks before launching production.
Further information may be obtained by consulting www.cea.fr
|VEDALAB shareholder change|
Dr Raphaël DONATI (the founder and current CEO of VEDALAB) has announced that VEDALAB SA and ALERE INC have concluded an agreement whereby the minority shares in VEDALAB SA, previously held by ALERE INC, have now been acquired by Dr Raphaël DONATI. The deal was officially concluded on 10 September 2014, thereby bringing to an end ALERE's presence as a shareholder in the VEDALAB company, a shareholding presence which it had occupied since 2006
*LEGIONELLA: Immunochromatographic rapid test for the qualitative detection of legionella in urine samples. Positive control is also available.
*STREPTOCOCCUS PNEUMONIAE: Immunochromatographic rapid test for the qualitative detection of Streptococcus pneumoniae in urine samples. Positive control is also available.